ProShares Ultra Nasdaq Biotechnology Stock Forecast, Price & News

+2.28 (+2.23 %)
(As of 09/21/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume28,219 shs
Average Volume118,695 shs
Market Capitalization$292.35 million
P/E RatioN/A
Dividend Yield0.00%
30 days | 90 days | 365 days | Advanced Chart
Receive BIB News and Ratings via Email

Sign-up to receive the latest news and ratings for ProShares Ultra Nasdaq Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

Basic Details

Issuer ProShares
Fund NameProShares Ultra Nasdaq Biotechnology
Tax ClassificationRegulated Investment Company
Inception Date4/6/2010
Fund ManagerMichael Neches, Tarak Dave

Fund Focus

Asset ClassEquity
BenchmarkNasdaq Biotech Index
FocusHealth Care
Development LevelDeveloped Markets
RegionNorth America

Fund Statistics

Assets Under Management$286.08 million
Average Daily Volume$44,486.50

ETF Expenses

Management Fee0.75%
Other Expenses0.29%
Total Expenses1.04%
Fee Waiver-0.09%
Net Expenses0.95%

Administrator, Advisor and Custodian

AdministratorJ.P. Morgan Investor Services Co.
AdvisorProShare Advisors LLC
CustodianJPMorgan Chase Bank, N.A.
DistributorSEI Investments Distribution Co.
Transfer AgentJPMorgan Chase Bank, N.A.
Lead Market MakerVirtu Financial

Geographic Exposure of BIB

Currency Exposure of BIB

Sector Exposure of BIB

Industry Exposure of BIB

speech bubbles
speech bubbles

ProShares Ultra Nasdaq Biotechnology (NYSEARCA:BIB) Frequently Asked Questions

What stocks does MarketBeat like better than ProShares Ultra Nasdaq Biotechnology?

Wall Street analysts have given ProShares Ultra Nasdaq Biotechnology a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ProShares Ultra Nasdaq Biotechnology wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

What other stocks do shareholders of ProShares Ultra Nasdaq Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ProShares Ultra Nasdaq Biotechnology investors own include Alibaba Group (BABA), Tencent (TCEHY), Biogen (BIIB), ACADIA Pharmaceuticals (ACAD), Gilead Sciences (GILD), KraneShares MSCI All China Health Care Index ETF (KURE), The Meet Group (MEET), SEA (SE), CRISPR Therapeutics (CRSP) and Cisco Systems (CSCO).

What is ProShares Ultra Nasdaq Biotechnology's stock symbol?

ProShares Ultra Nasdaq Biotechnology trades on the New York Stock Exchange (NYSE)ARCA under the ticker symbol "BIB."

How do I buy shares of ProShares Ultra Nasdaq Biotechnology?

Shares of BIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ProShares Ultra Nasdaq Biotechnology's stock price today?

One share of BIB stock can currently be purchased for approximately $104.41.

How much money does ProShares Ultra Nasdaq Biotechnology make?

ProShares Ultra Nasdaq Biotechnology has a market capitalization of $292.35 million.

This page was last updated on 9/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.